Navigation Links
Regulus Announces $80.9 Million in Total Gross Proceeds from IPO and Other Recent Financial Transactions
Date:11/5/2012

LA JOLLA, Calif., Nov. 5, 2012 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, summarized today its recent financing activity that the company expects will enable Regulus to execute its current strategic objectives for the foreseeable future.

In connection with Regulus' Initial Public Offering (IPO), which closed on October 10, 2012, and other recent financial transactions, Regulus has raised $80.9 million in gross proceeds, including:

  • $50.9 million from the sale of common stock in the IPO, inclusive of an over-allotment option exercise by the underwriters and insider participation by Isis Pharmaceuticals, Inc., one of our founding companies, and two of our strategic partners, Sanofi and GSK;
  • $25.0 million from the sale of common stock in a private placement to AstraZeneca AB, one of Regulus' strategic partners, that closed concurrently with the IPO; and
  • $5.0 million from the sale of a convertible note in August 2012 to Biogen Idec, one of Regulus' research collaborators, which converted into shares of common stock at the completion of the IPO.

"We are excited to have reached this important point in Regulus' life," said Kleanthis G. Xanthopoulos, Ph.D., President and CEO of Regulus. "With the company well capitalized for the foreseeable future, we are focused on building a meaningful clinical portfolio and realizing the transformative potential of microRNA therapeutics."

About Regulus

Regulus Therapeutics Inc. (NASDAQ: RGLS) is a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs. Regulus is leveraging a mature therapeutic platform based on technology that has been developed over 20 years. Regulus works with a broad network of academic collaborator
'/>"/>

SOURCE Regulus Therapeutics Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Regulus Therapeutics Forms Strategic Alliance for Discovery, Development and Commercialization of microRNA Therapeutics with AstraZeneca
2. Biogen Idec and Regulus Therapeutics Form Collaboration to Explore microRNA Biomarkers for Disease Monitoring and Response to Therapy
3. Regulus Presents New Preclinical Data on miR-21 at Kidney Week 2012
4. Precision Optics Corporation Announces $1 Million Order for Microprecision™ Based Endoscopes
5. Young Innovations, Inc. Announces Record Sales and EPS for the Quarter Ended March 31, 2012
6. JDRF Announces Research Collaboration with Dexcom, Inc. to Develop "Smart Transmitter" Technology to Accelerate Artificial Pancreas Studies
7. Misonix Announces New Distribution Agreement For Panama
8. University of Maryland BioPark Announces MedImmunes Dr. Bahija Jallal as Newest Member of Board of Directors for UM Health Sciences Research Park
9. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
10. Boston Scientific Announces CE Mark and European Launch of Emerge™ PTCA Dilatation Catheter
11. Soligenix Announces Further Progress with ThermoVax™ for Long-Term Vaccine ThermoStability
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... Jan. 23, 2015 For the pharmaceutical industry, marketplace success ... payers. Likewise, the importance of the managed markets function - ... to grow as payer formularies and provider networks play an ... At the same time, managed markets leaders must continually identify ...
(Date:1/23/2015)... ANGELES , Jan. 23, 2015 A lot of ... best methods for treating  certain illnesses, injuries, or conditions. As ... replace previous treatment methods with ones that they consider to ... hernias, there is not one textbook method of treatment that ...
(Date:1/23/2015)... , Jan. 23, 2015  A new analysis of ... D 2015 enrollment data shows that 81 percent of ... access and extra discounts at certain pharmacies. The findings ... "Preferred pharmacy plans are now the foundation of Medicare ...
Breaking Medicine Technology:As Payer Influence Rises, Pharmaceutical Companies work to Optimize the Managed Markets Function 2No One-Size-Fits-All Remedy for Hernia Correction 2New Analysis: 81 Percent of Medicare Part D Seniors Choose "Preferred Pharmacy" Plans in 2015 2
... YORK, Nov. 5 - Top experts from the,Alzheimer,s ... widespread,utilization of memory screenings, especially in light of ... are not recognized,often enough and that early diagnosis ... Eric J. Hall, AFA,s chief executive officer, ...
... Nov. 5 Synvista Therapeutics,Inc. (Amex: SYI ... as the ICARE,study, being presented today at the ... Florida. The study demonstrated that,supplementing Vitamin E therapy ... Haptoglobin 2-2 (Hp2-2) phenotype met its pre-specified, primary,endpoint ...
Cached Medicine Technology:Experts Call for Widespread Use of Memory Screenings and Emphasize Value of Early Detection of Dementia 2Experts Call for Widespread Use of Memory Screenings and Emphasize Value of Early Detection of Dementia 3Experts Call for Widespread Use of Memory Screenings and Emphasize Value of Early Detection of Dementia 4Synvista Therapeutics Highlights New Data Demonstrating the Clinical Benefit of Vitamin E Therapy in Patients Identified on the Basis of Haptoglobin Phenotype Testing 2Synvista Therapeutics Highlights New Data Demonstrating the Clinical Benefit of Vitamin E Therapy in Patients Identified on the Basis of Haptoglobin Phenotype Testing 3Synvista Therapeutics Highlights New Data Demonstrating the Clinical Benefit of Vitamin E Therapy in Patients Identified on the Basis of Haptoglobin Phenotype Testing 4
(Date:1/22/2015)... (PRWEB) January 22, 2015 For over 20 years, ... Oceanside and Vista area has treated just about every ... personal injury circumstances. And for those same twenty-plus years, the ... of all those injuries with the best possible doctor. ...
(Date:1/22/2015)... 22, 2015 Yesterday, Senator Holly ... and Kristin Olsen (R-Modesto) were honored by the ... advancing biotechnology, biomedical science, medical device and pharmaceutical ... received the “2014 Life Sciences Champion” award from ...
(Date:1/22/2015)... Payday lending practices in four southern ... financial distress to the states that permit them, according ... Center on Race and Wealth. , While they generate ... loans at the same time substantially depress economic activity, ...
(Date:1/22/2015)... Compare-autoinsurance.org has released a new blog post presenting a ... insurance policy . , Some types of vehicles cannot be ... newly released blog post to see if their vehicle qualifies for ... are some of the cars that cannot be covered by a ...
(Date:12/26/2014)... 2014 The US represents the largest market ... 2013, GlobalData’s forecast estimates that sales of branded therapies were ... to the high incidence of the disease, high drug treatment ... and China. Increased sales of CRC therapies over the forecast ...
Breaking Medicine News(10 mins):Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 3Health News:Howard University Spotlights the Economic Impact of Payday Lending in Southern States 2Health News:Some Vehicles Cannot Be Covered By An Auto Insurance Policy! 2Health News:US Colorectal Cancer Drug Market Analysis and Forecast to 2023 Report Available at ReportsnReports.com 2Health News:US Colorectal Cancer Drug Market Analysis and Forecast to 2023 Report Available at ReportsnReports.com 3Health News:US Colorectal Cancer Drug Market Analysis and Forecast to 2023 Report Available at ReportsnReports.com 4
... , BEDFORD, Mass., July 13 Hologic, Inc. (Hologic ... leading developer, manufacturer and supplier of premium diagnostics, medical ... healthcare needs of women, today announced plans to release ... August 3, 2009 after market close. In conjunction with ...
... July 13 Long term care costs in Wyoming continue ... pressure on those in or near retirement. As a leader ... suite of insurance products to help people proactively plan for ... take advantage of a new program designed to simplify the ...
... WALTHAM, Mass., July 13 Decision Resources, one of the ... healthcare issues, finds that the rheumatoid arthritis (RA) drug market ... in 2008 to $385 million in 2013. This growth will ... to healthcare insurance, greater patient spending power and increased use ...
... , , , ... July 13 CareGuide, Inc., an emerging health management company, welcomes ... as Area Vice President of Sales. Both are located in Texas ... location. , , Julie Sizemore ( ...
... RATON, Fla., July 13 Laura E. Skellchock, M.D. at Integrative ... collagen filler for the correction of smile lines, to treat patients ... has been an avid Artefill user the past several years due ... , , "It,s the perfect ...
... Calif., July 13 Sit ,n Sleep, the mattress ... millions of Southern Californians, today launched a new campaign ... right mattress and improved sleep health and well-being. Widely-known ... in town, Sit ,n Sleep,s new strategic direction ...
Cached Medicine News:Health News:Hologic to Release Third Quarter Fiscal 2009 Operating Results on Monday, August 3, 2009 2Health News:Genworth Financial Simplifies the Process of Purchasing Affordable Long Term Care Insurance for Wyoming AARP Members 2Health News:Genworth Financial Simplifies the Process of Purchasing Affordable Long Term Care Insurance for Wyoming AARP Members 3Health News:Genworth Financial Simplifies the Process of Purchasing Affordable Long Term Care Insurance for Wyoming AARP Members 4Health News:Genworth Financial Simplifies the Process of Purchasing Affordable Long Term Care Insurance for Wyoming AARP Members 5Health News:China's Rheumatoid Arthritis Drug Market Will More than Double by 2013 2Health News:China's Rheumatoid Arthritis Drug Market Will More than Double by 2013 3Health News:CareGuide Adds New Management Team Members 2Health News:Integrative Dermatology of Boca Raton Selects Artefill to Meet Growing Patient Demand for a Longer Lasting Dermal Filler 2Health News:Integrative Dermatology of Boca Raton Selects Artefill to Meet Growing Patient Demand for a Longer Lasting Dermal Filler 3Health News:Sit 'n Sleep Refocuses on Consumer Sleep Health and Well-Being 2Health News:Sit 'n Sleep Refocuses on Consumer Sleep Health and Well-Being 3Health News:Sit 'n Sleep Refocuses on Consumer Sleep Health and Well-Being 4
Ergonomically designed, the Invacare Printing Pulse Oximeter provides fast, reliable spot-check information and documentation of SpO2 and pulse rate. It is ideal for all patients from neonate to adul...
The reliable and easy-to-use 3800 pulse oximeter is now more advanced - featuring TruTrak+ technology, the proprietary clinical motion algorithm from Datex+-Ohmeda....
... 8600 Series Tabletop/Portable Digital Pulse ... tool for patient monitering. From ... the 8600 has earned the ... and is recognized for its ...
... Resolve Immersion Oil is a clear, ... throughout most of the UV-VIS spectrum. ... and high viscosity, is non-drying and ... of 1.5150. Resolve contains no PCBs, ...
Medicine Products: